Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reproducibility of 11C-PBR28 PET Signal
NCT02086240Withdrawn
- Sponsor
- Imperial College London
- Start
- Mar 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emapunil in multiple sclerosis (MS) and Neurodegenerative disorders (NDDs), sponsored by Imperial College London. Primary endpoint: TSPO Binding Status. Planned start Mar 2014; status: withdrawn.
02
Drugs
emapunil
03
Conditions
multiple sclerosis (MS)Neurodegenerative disorders (NDDs)
Beyond the preview
Go deeper on NCT02086240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086240.